Eli Lilly and Company (NYSE:LLY) Trading Down 1.2% – Here’s Why

Eli Lilly and Company (NYSE:LLY) traded down 1.2% during mid-day trading on Tuesday . The stock traded as low as $1,229.79 and last traded at $1,231.9650. Approximately 2,124,000 shares were traded during mid-day trading, a decline of 31% from the average session volume of 3,090,796 shares. The stock had previously closed at $1,246.93.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Foundayo expands Lilly’s oral obesity-drug opportunity. The company launched its once-daily weight-loss and diabetes pill in the U.K., giving patients an oral alternative to injectable GLP-1 treatments and creating a potential new growth channel in Europe. Eli Lilly launches oral weight-loss pill Foundayo in UK
• Positive Sentiment: FDA clearance adds a diagnostics catalyst. The FDA cleared an Alzheimer’s blood test developed by Roche and Eli Lilly to help identify signs of disease in people aged 55 and older with cognitive decline. The test could broaden Lilly’s commercial exposure beyond diabetes and obesity therapies. Roche, Eli Lilly’s Alzheimer’s blood test gets FDA clearance
• Positive Sentiment: Investor and pipeline support remains strong. Citadel reportedly increased its Eli Lilly position nearly fourfold to roughly $1.1 billion, while early-stage studies of LY4395089 and LY3549492 continue to advance. These developments reinforce confidence in Lilly’s long-term pipeline, although neither experimental program is yet a near-term revenue driver. Eli Lilly Stock in Focus as Hedge Fund Titan Ken Griffin Quadruples Position
• Neutral Sentiment: Competitive comparisons are favorable but valuation is demanding. Analysts continue to point to Lilly’s stronger growth outlook versus some large pharmaceutical peers and Novo Nordisk. However, commentary also highlights that the shares already reflect significant future success, making further gains dependent on sustained execution and guidance upgrades. Eli Lilly Stock Raised Its Forecast, So Why Is the Market Shrugging?
• Negative Sentiment: Coverage concerns are weighing on demand expectations. Some employers and companies are declining to cover weight-loss medicines, viewing obesity treatments as optional rather than essential care. Any limits on reimbursement could slow patient adoption, pressure pricing, and temper expectations for Lilly’s GLP-1 revenue growth. Eli Lilly Stock Rattled as Companies Decline to Cover Weight-Loss Drug Costs

Analyst Upgrades and Downgrades

LLY has been the subject of a number of recent research reports. Guggenheim raised their price objective on shares of Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the stock a “buy” rating in a research note on Monday, July 13th. Wells Fargo & Company upped their target price on Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Wolfe Research reiterated an “outperform” rating and set a $1,350.00 target price on shares of Eli Lilly and Company in a report on Thursday, May 21st. JPMorgan Chase & Co. boosted their price target on Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the stock an “overweight” rating in a report on Tuesday, July 7th. Finally, The Goldman Sachs Group restated a “buy” rating and issued a $1,283.00 price objective on shares of Eli Lilly and Company in a research report on Friday, May 22nd. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,292.18.

Eli Lilly and Company Trading Down 1.2%

The business has a 50 day simple moving average of $1,182.50 and a two-hundred day simple moving average of $1,061.66. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. The company has a market cap of $1.16 trillion, a PE ratio of 41.34, a price-to-earnings-growth ratio of 1.48 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The business had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. During the same quarter in the previous year, the business earned $6.31 earnings per share. The business’s revenue for the quarter was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, analysts forecast that Eli Lilly and Company will post 36.35 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is presently 23.22%.

Insider Buying and Selling

In related news, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the sale, the executive vice president directly owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the sale, the chief accounting officer owned 1,526 shares of the company’s stock, valued at approximately $1,808,325.26. The trade was a 56.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 13,500 shares of company stock valued at $15,958,170. Insiders own 0.14% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Osbon Capital Management LLC purchased a new stake in shares of Eli Lilly and Company during the 4th quarter worth about $25,000. Basso Capital Management L.P. purchased a new position in Eli Lilly and Company in the fourth quarter valued at approximately $30,000. Maseco LLP lifted its position in Eli Lilly and Company by 466.7% during the first quarter. Maseco LLP now owns 34 shares of the company’s stock valued at $31,000 after buying an additional 28 shares in the last quarter. E Fund Management Hong Kong Co. Ltd. lifted its position in Eli Lilly and Company by 342.9% during the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after buying an additional 24 shares in the last quarter. Finally, Aventus Investment Advisors Inc. increased its position in shares of Eli Lilly and Company by 270.0% in the first quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company’s stock worth $34,000 after acquiring an additional 27 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.